Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Open-Label, Multi-Center Study of SNG1005 Compared With Physician's Best Choice in HER2-Negative Breast Cancer Patients With Brain Metastases After Whole Brain Radiotherapy

Next Previous
Trial Profile

A Randomized Open-Label, Multi-Center Study of SNG1005 Compared With Physician's Best Choice in HER2-Negative Breast Cancer Patients With Brain Metastases After Whole Brain Radiotherapy

Status: Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel trevatide (Primary)
  • Indications Advanced breast cancer; Brain metastases; Carcinoma; HER2 negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 11 Nov 2019 Status changed from planning to not yet recruiting.
  • 09 Aug 2019 New trial record
  • 05 Aug 2019 According to an Innovent Biologics Media release, the Investigational New Drug (IND) application of SNG1005's Phase II/III clinical trial for the treatment of breast cancer carcinoma brain metastases (BCBS) in China has been approved by the National Medical Products Administration (NMPA), and the clinical trial is planned.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top